Proteomic-based investigations on the mode of action of the marine anticancer compound rhizochalinin

Standard

Proteomic-based investigations on the mode of action of the marine anticancer compound rhizochalinin. / Dyshlovoy, Sergey A; Otte, Katharina; Venz, Simone; Hauschild, Jessica; Junker, Heike; Makarieva, Tatyana N; Balabanov, Stefan; Alsdorf, Winfried H; Madanchi, Ramin; Honecker, Friedemann; Bokemeyer, Carsten; Stonik, Valentin A; von Amsberg, Gunhild.

in: PROTEOMICS, Jahrgang 17, Nr. 11, 06.2017.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsätzeForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{51c0e51f18d14b94ad116467f990f21c,
title = "Proteomic-based investigations on the mode of action of the marine anticancer compound rhizochalinin",
abstract = "Rhizochalinin (Rhiz) is a novel marine natural sphingolipid-like compound, which shows promising in vitro and in vivo activity in human castration-resistant prostate cancer. In the present study, a global proteome screening approach was applied to investigate molecular targets and biological processes affected by Rhiz in castration-resistant prostate cancer. Bioinformatical analysis of the data predicted an antimigratory effect of Rhiz on cancer cells. Validation of proteins involved in the cancer-associated processes, including cell migration and invasion, revealed downregulation of specific isoforms of stathmin and LASP1, as well as upregulation of Grp75, keratin 81, and precursor IL-1β by Rhiz. Functional analyses confirmed an antimigratory effect of Rhiz in PC-3 cells. Additionally, predicted ERK1/2 activation was confirmed by Western blotting analysis, and revealed prosurvival effects in Rhiz-treated prostate cancer cells indicating a potential mechanism of resistance. A combination of Rhiz with MEK/ERK inhibitors PD98059 (non-ATP competitive MEK1 inhibitor) and FR180204 (ATP-competitive ERK1/2 inhibitor) resulted in synergistic effects. This work provides further insights into the molecular mechanisms underlying Rhiz bioactivity. Furthermore, our research is exemplary for the ability of proteomics to predict drug targets and mode of action of natural anticancer agents.",
keywords = "Journal Article",
author = "Dyshlovoy, {Sergey A} and Katharina Otte and Simone Venz and Jessica Hauschild and Heike Junker and Makarieva, {Tatyana N} and Stefan Balabanov and Alsdorf, {Winfried H} and Ramin Madanchi and Friedemann Honecker and Carsten Bokemeyer and Stonik, {Valentin A} and {von Amsberg}, Gunhild",
note = "{\textcopyright} 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.",
year = "2017",
month = jun,
doi = "10.1002/pmic.201700048",
language = "English",
volume = "17",
journal = "PROTEOMICS",
issn = "1615-9853",
publisher = "Wiley-VCH Verlag GmbH",
number = "11",

}

RIS

TY - JOUR

T1 - Proteomic-based investigations on the mode of action of the marine anticancer compound rhizochalinin

AU - Dyshlovoy, Sergey A

AU - Otte, Katharina

AU - Venz, Simone

AU - Hauschild, Jessica

AU - Junker, Heike

AU - Makarieva, Tatyana N

AU - Balabanov, Stefan

AU - Alsdorf, Winfried H

AU - Madanchi, Ramin

AU - Honecker, Friedemann

AU - Bokemeyer, Carsten

AU - Stonik, Valentin A

AU - von Amsberg, Gunhild

N1 - © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

PY - 2017/6

Y1 - 2017/6

N2 - Rhizochalinin (Rhiz) is a novel marine natural sphingolipid-like compound, which shows promising in vitro and in vivo activity in human castration-resistant prostate cancer. In the present study, a global proteome screening approach was applied to investigate molecular targets and biological processes affected by Rhiz in castration-resistant prostate cancer. Bioinformatical analysis of the data predicted an antimigratory effect of Rhiz on cancer cells. Validation of proteins involved in the cancer-associated processes, including cell migration and invasion, revealed downregulation of specific isoforms of stathmin and LASP1, as well as upregulation of Grp75, keratin 81, and precursor IL-1β by Rhiz. Functional analyses confirmed an antimigratory effect of Rhiz in PC-3 cells. Additionally, predicted ERK1/2 activation was confirmed by Western blotting analysis, and revealed prosurvival effects in Rhiz-treated prostate cancer cells indicating a potential mechanism of resistance. A combination of Rhiz with MEK/ERK inhibitors PD98059 (non-ATP competitive MEK1 inhibitor) and FR180204 (ATP-competitive ERK1/2 inhibitor) resulted in synergistic effects. This work provides further insights into the molecular mechanisms underlying Rhiz bioactivity. Furthermore, our research is exemplary for the ability of proteomics to predict drug targets and mode of action of natural anticancer agents.

AB - Rhizochalinin (Rhiz) is a novel marine natural sphingolipid-like compound, which shows promising in vitro and in vivo activity in human castration-resistant prostate cancer. In the present study, a global proteome screening approach was applied to investigate molecular targets and biological processes affected by Rhiz in castration-resistant prostate cancer. Bioinformatical analysis of the data predicted an antimigratory effect of Rhiz on cancer cells. Validation of proteins involved in the cancer-associated processes, including cell migration and invasion, revealed downregulation of specific isoforms of stathmin and LASP1, as well as upregulation of Grp75, keratin 81, and precursor IL-1β by Rhiz. Functional analyses confirmed an antimigratory effect of Rhiz in PC-3 cells. Additionally, predicted ERK1/2 activation was confirmed by Western blotting analysis, and revealed prosurvival effects in Rhiz-treated prostate cancer cells indicating a potential mechanism of resistance. A combination of Rhiz with MEK/ERK inhibitors PD98059 (non-ATP competitive MEK1 inhibitor) and FR180204 (ATP-competitive ERK1/2 inhibitor) resulted in synergistic effects. This work provides further insights into the molecular mechanisms underlying Rhiz bioactivity. Furthermore, our research is exemplary for the ability of proteomics to predict drug targets and mode of action of natural anticancer agents.

KW - Journal Article

U2 - 10.1002/pmic.201700048

DO - 10.1002/pmic.201700048

M3 - SCORING: Journal articles

C2 - 28445005

VL - 17

JO - PROTEOMICS

JF - PROTEOMICS

SN - 1615-9853

IS - 11

ER -